1. Scrip
  3. >>Japan

Banking Crisis Prompts Postponed Noile-Immune IPO, But Wider Japan Views Mixed

 
• By Lisa Takagi

While the SVB and wider banking crisis has shaken VCs and bioventures in the US and Europe, Japan has mixed view on its impact and the government is keeping an eye on the situation. But one biotech has nevertheless cautiously decided to withdraw from a market listing despite Tokyo Exchange Market approval.

Although not fearing the direct impact from the global banking crisis, Japan’s biotech/bioventure market in in a cautious for its potential impact.
Although not fearing the direct impact from the global banking crisis, Japan’s biotech/bioventure market is in a cautious for its potential impact. • Source: Shutterstock

As the financial crisis triggered by the bankruptcy of Silicon Valley Bank (SVB) expands globally, Japan’s bioventure/biotech sector has mixed views on its impact.

Because both the market and funding base from domestic venture capital funds is smaller compared to the US, so is the estimation of the effect of SVB and the wider banking crisis, especially as the industry has already seen challenges to

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Focus On Asia